Abstract 4558
Background
Response of desmoid tumors (DT) to chemotherapy (CT) is evaluated according to RECIST criteria in daily practice and clinical trials. However, MRI demonstrates early change in heterogeneity in responding tumor, due to decrease in cellular area and increase in fibro-necrotic content, before dimensional response. Heterogeneity can be quantified through radiomics approach. Aim was to develop radiomics-based response criteria and to compare their performances with usual criteria.
Methods
43 patients (28 women, median age: 38.2) were prospectively included in this ancillary multicentre study of a randomized phase II trial (NCT01876082) as they presented with progressive DT, contrast-enhanced MRI at baseline (MRI-0) and early evaluation (3 months later, MRI-1). After signal intensities normalization, voxel size standardization and segmentation of whole DT volume on fat-suppressed contrast-enhanced T1-weighted imaging, 90 baseline and delta 3D-radiomics features (RF) were extracted. Using least absolute shrinkage and selection operator with Cox regression model and cross validation, a radiomics score based on selected and weighted RF was generated. The performances of prognostic models based on radiomics score, RECIST, mRECIST, EASL, Cheson, Choi and modified-Choi criteria from MRI-0 to MRI-1 to predict progression-free survival (PFS) were assessed with concordance-index. All the results were adjusted for ECOG performance status, initial tumor volume, prior CTs, current CT and B-catenin mutation. Usual response criteria were evaluated in both disease control and objective response settings.
Results
There were 11 progressions. The radiomics score included 4 variables (1 baseline RF and 3 delta-RF). A high radiomics score indicated a poorer prognosis. The radiomics score significantly correlated with PFS (adjusted hazard ratio = 3.39, 95%CI = [1.47-7.79], p = 0.0043) while none of the usual response criteria was (range of p-values = [0.166-0.750]). The prognostic model based on radiomics score had the highest concordance-index (0.794, 95%CI = [0.678-0.910]).
Conclusions
Quantifying heterogeneity with MRI at baseline and its early change through a dedicated radiomics score can improve the response evaluation for DT treated with CT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Antoine Italiano.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5011 - LCSCAF1 maintains cancer stem-like traits by stabilizing c-Myc protein and promotes metastasis and recurrence in lung cancer
Presenter: Tao Guo
Session: Poster Display session 1
Resources:
Abstract
4955 - XAF1 Enhances Temozolomide Induced Autophagic Cell Death through AMPK signaling pathway
Presenter: Mingoo Lee
Session: Poster Display session 1
Resources:
Abstract
5616 - The effect of cortisol on methylation patterns in breast cancer cell lines
Presenter: Haya Intabli
Session: Poster Display session 1
Resources:
Abstract
4649 - Global and sex-specific epigenome-wide association studies for the identification of the main methylated loci related to smoking in a Mediterranean population
Presenter: Judith Begona Ramirez Sabio
Session: Poster Display session 1
Resources:
Abstract
4984 - Whole transcriptomics analyses of mimicking Circulating Tumor Cells (CTCs) by single-cell RNA sequencing (scRNAseq)
Presenter: Jessica Garcia
Session: Poster Display session 1
Resources:
Abstract
5926 - Comparison of enzymatic- and bisulfite conversion to map the plasma cell-free methylome in cancer
Presenter: Nicole Lambert
Session: Poster Display session 1
Resources:
Abstract
5454 - Detection of low mutations in hepatocellular carcinoma by using circulating tumor DNA
Presenter: Esl Kim
Session: Poster Display session 1
Resources:
Abstract
4428 - Variants in the JAK1 and JAK2 genes in the risk and prognosis of patients with cutaneous melanoma
Presenter: Bruna Carvalho
Session: Poster Display session 1
Resources:
Abstract
4409 - P-Rex1 expression in breast cancer patients.
Presenter: Angela Lara Montero
Session: Poster Display session 1
Resources:
Abstract
4185 - Modulation of Risk of Cutaneous Melanoma Patients by Variants in STAT3 Gene and Functional Analysis
Presenter: Gabriela Gomez
Session: Poster Display session 1
Resources:
Abstract